Top

Published in:

01-12-2021 | Breast Cancer | Correction

Correction to: Molecular analyses of triple-negative breast cancer in the young and elderly

Authors: Mattias Aine, Ceren Boyaci, Johan Hartman, Jari Häkkinen, Shamik Mitra, Ana Bosch Campos, Emma Nimeus, Anna Ehinger, Johan Vallon-Christersson, Åke Borg, Johan Staaf

Published in: Breast Cancer Research | Issue 1/2021

Excerpt

Correction to: Breast Cancer Res (2021) 23:20 …

Aine M, et al. Molecular analyses of triple-negative breast cancer in the young and elderly. Breast Cancer Res. 2021;23:20. https://doi.org/10.1186/s13058-021-01392-0.CrossRef

Title: Correction to: Molecular analyses of triple-negative breast cancer in the young and elderly
Authors: Mattias Aine
Ceren Boyaci
Johan Hartman
Jari Häkkinen
Shamik Mitra
Ana Bosch Campos
Emma Nimeus
Anna Ehinger
Johan Vallon-Christersson
Åke Borg
Johan Staaf
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer Research / Issue 1/2021
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/s13058-021-01405-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

Low thyroid hormone receptor alpha-2 (THRα-2) tumor expression is associated with unfavorable tumor characteristics and high breast cancer mortality

IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study

Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992–2016

Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA

Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study

Molecular analyses of triple-negative breast cancer in the young and elderly

Keynote webinar | Spotlight on antibody–drug conjugates in cancer